MA53827A - Modulateurs de l'alpha -1 antitrypsine - Google Patents

Modulateurs de l'alpha -1 antitrypsine

Info

Publication number
MA53827A
MA53827A MA053827A MA53827A MA53827A MA 53827 A MA53827 A MA 53827A MA 053827 A MA053827 A MA 053827A MA 53827 A MA53827 A MA 53827A MA 53827 A MA53827 A MA 53827A
Authority
MA
Morocco
Prior art keywords
alpha
antitrypsin
modulators
antitrypsin modulators
Prior art date
Application number
MA053827A
Other languages
English (en)
Inventor
Upul Keerthi Bandarage
Cavan Mckeon Bligh
Diane M Boucher
Michael John Boyd
Michael Aaron Brodney
Kevin Michael Cottrell
Veronique Damagnez
Fanning Lev Tyler Dewey
Mary Elizabeth Eccles
Jr Robert Francis Fimognari
Kevin James Gagnon
Barrantes Pedro M Garcia
Simon Giroux
Jr Ronald Lee Grey
Amy Beth Hall
Sarah Carol Hood
Dennis James Hurley
Joshua Kennedy Hussey
Jr Mac Arthur Johnson
Peter Jones
Sarathy Kesavan
Adam Looker
Brad D Maxwell
John Patrick Maxwell
Ales Medek
Mettachit Navamal
Philippe Marcel Nuhant
Setu Roday
Stefanie Roeper
Rupa Sawant
Yi Shi
Rebecca Jane Swett
Qing Tang
Timothy Lewis Tapley
Stephen A Thomson
Michael Waldo
Jinwang Xu
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MA53827A publication Critical patent/MA53827A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA053827A 2018-10-05 2019-10-04 Modulateurs de l'alpha -1 antitrypsine MA53827A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862742148P 2018-10-05 2018-10-05
US201862768662P 2018-11-16 2018-11-16

Publications (1)

Publication Number Publication Date
MA53827A true MA53827A (fr) 2021-09-15

Family

ID=69467663

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053827A MA53827A (fr) 2018-10-05 2019-10-04 Modulateurs de l'alpha -1 antitrypsine

Country Status (16)

Country Link
US (2) US11623924B2 (fr)
EP (1) EP3860712A1 (fr)
JP (1) JP2022512588A (fr)
KR (1) KR20210089656A (fr)
CN (1) CN113164761A (fr)
AU (1) AU2019362753A1 (fr)
BR (1) BR112021006392A2 (fr)
CA (1) CA3114672A1 (fr)
CO (1) CO2021005884A2 (fr)
IL (1) IL281884A (fr)
JO (1) JOP20210060A1 (fr)
MA (1) MA53827A (fr)
MX (1) MX2021003819A (fr)
TW (1) TW202024091A (fr)
UY (1) UY38403A (fr)
WO (1) WO2020081257A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164761A (zh) 2018-10-05 2021-07-23 弗特克斯药品有限公司 α-1抗胰蛋白酶的调节剂
UY38696A (es) * 2019-05-14 2020-11-30 Vertex Pharma Moduladores de alfa-1 antitripsina
TW202116303A (zh) * 2019-10-02 2021-05-01 美商維泰克斯製藥公司 α—1抗胰蛋白酶缺乏症之治療方法
GB201918404D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of aplha1-antitrypsin deficiency
GB201918413D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB201918416D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
GB201918414D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
GB201918410D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
BR112022019794A2 (pt) * 2020-04-03 2022-12-06 Vertex Pharma Derivados de pirrolo[2,3-f]indazol e 2,4,5,10-tetrazatriciclo[7.3.0.03,7]dodeca-1,3(7),5,8,11- penteno como moduladores da alfa-1-antitripsina para tratamento da deficiência de alfa-1-antitripsina (aatd)
GB202009074D0 (en) 2020-06-15 2020-07-29 Z Factor Ltd Compound
KR20230044478A (ko) 2020-07-27 2023-04-04 버텍스 파마슈티칼스 인코포레이티드 Alpha-1 항트립신 조절제 제조 방법
US20240012010A1 (en) 2020-11-12 2024-01-11 Vertex Pharmaceuticals Incorporated Methods of monitoring alpha-1 antitrypsin (aat) deficiency by measuring polymerised aat
CN116897157A (zh) * 2020-11-17 2023-10-17 弗特克斯药品有限公司 4-(5-(4-氟苯基)-6-(四氢-2h-吡喃-4-基)-1,5-二氢吡咯并[2,3-f]吲唑-7-基)苯甲酸的固体形式
GB202108523D0 (en) 2021-06-15 2021-07-28 Z Factor Ltd Compositions and their use for the treatment of alpha1-antitrypsin deficiency
CN114605385B (zh) * 2022-03-25 2023-09-08 河南大学 吲哚哌啶脲类trpv1拮抗/faah抑制双靶点药物及制备方法和应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) * 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
DK158590D0 (da) 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
JP2000072751A (ja) 1998-08-26 2000-03-07 Tanabe Seiyaku Co Ltd イソキノリノン誘導体
JP2000281654A (ja) 1999-03-26 2000-10-10 Tanabe Seiyaku Co Ltd イソキノリン誘導体
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
FR2802532A1 (fr) 1999-12-17 2001-06-22 Sanofi Synthelabo Derives de 2-phenyl-quinoleine, leur preparation et leur application en therapeutique
US6638929B2 (en) 1999-12-29 2003-10-28 Wyeth Tricyclic protein kinase inhibitors
HUP0300721A3 (en) 2000-07-26 2006-02-28 Smithkline Beecham Plc Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity, process for producing them, pharmaceutical compositions containing them and use thereof
WO2002094790A1 (fr) 2001-05-23 2002-11-28 Mitsubishi Pharma Corporation Compose heterocyclique condense et son utilisation medicale
HUP0501067A2 (en) 2001-11-14 2006-02-28 Teva Pharma Amorphous and crystalline forms of losartan potassium and process for their preparation
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
WO2011056222A1 (fr) * 2009-11-05 2011-05-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Procédés de traitement de troubles associés à une agrégation protéique
US20110224229A1 (en) 2010-03-10 2011-09-15 Astrazeneca Ab Novel Crystalline Form
US9572794B2 (en) 2014-08-06 2017-02-21 Vanderbilt University Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists
WO2016154051A1 (fr) 2015-03-20 2016-09-29 University Of Florida Research Foundation, Inc. Polythérapie pour le traitement de maladies infectieuses
JP2019516700A (ja) 2016-05-12 2019-06-20 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ash1l阻害剤及びそれを用いた治療方法
EP3699179A4 (fr) 2017-10-19 2021-06-16 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Dérivé tricyclique contenant du pyrazolyle, son procédé de préparation et son utilisation
KR20200081434A (ko) 2017-11-01 2020-07-07 브리스톨-마이어스 스큅 컴퍼니 파르네소이드 x 수용체 조정제로서의 가교된 비시클릭 화합물
CN107698505A (zh) 2017-11-20 2018-02-16 孙婷婷 一种诺得司他的制备方法
US11459330B2 (en) 2017-12-13 2022-10-04 Lupin Limited Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors
JP7316288B2 (ja) 2018-01-31 2023-07-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Irak阻害剤としてのキノリン化合物及びその使用
EP3810131A1 (fr) 2018-06-22 2021-04-28 UCL Business Ltd Nouveaux composés
BR112021002267A8 (pt) 2018-08-07 2023-02-07 Merck Sharp & Dohme Inibidores de prmt5
CN113164761A (zh) 2018-10-05 2021-07-23 弗特克斯药品有限公司 α-1抗胰蛋白酶的调节剂
CN110776459B (zh) 2019-03-19 2023-01-24 江苏知原药业股份有限公司 7-羟基-2-喹诺酮-二硫代氨基甲酸酯类胆碱酯酶抑制剂
UY38696A (es) 2019-05-14 2020-11-30 Vertex Pharma Moduladores de alfa-1 antitripsina
TW202116303A (zh) 2019-10-02 2021-05-01 美商維泰克斯製藥公司 α—1抗胰蛋白酶缺乏症之治療方法
JP2023513018A (ja) 2020-01-30 2023-03-30 バーテックス ファーマシューティカルズ インコーポレイテッド アルファ-1アンチトリプシン欠乏症の治療方法
JP2023520400A (ja) 2020-04-03 2023-05-17 バーテックス ファーマシューティカルズ インコーポレイテッド アルファ-1-アンチトリプシン欠損症(aatd)を治療するためのアルファ-1-アンチトリプシンモジュレーターとしてのインドール誘導体
CN115715292A (zh) 2020-04-03 2023-02-24 弗特克斯药品有限公司 作为用于治疗α-1-抗胰蛋白酶缺乏症(AATD)的α-1-抗胰蛋白酶调节剂的1H-吡唑并[4,3-g]异喹啉和1H-吡唑并[4,3-g]喹啉衍生物
BR112022019794A2 (pt) 2020-04-03 2022-12-06 Vertex Pharma Derivados de pirrolo[2,3-f]indazol e 2,4,5,10-tetrazatriciclo[7.3.0.03,7]dodeca-1,3(7),5,8,11- penteno como moduladores da alfa-1-antitripsina para tratamento da deficiência de alfa-1-antitripsina (aatd)
US20230339915A1 (en) 2020-04-03 2023-10-26 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
CA3179189A1 (fr) 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated Modulateurs d'alpha 1 antitrypsine
US20230157999A1 (en) 2020-04-03 2023-05-25 Vertex Pharmaceuticals Incorporated Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (aatd)
KR20230044478A (ko) 2020-07-27 2023-04-04 버텍스 파마슈티칼스 인코포레이티드 Alpha-1 항트립신 조절제 제조 방법

Also Published As

Publication number Publication date
JP2022512588A (ja) 2022-02-07
MX2021003819A (es) 2021-06-23
KR20210089656A (ko) 2021-07-16
BR112021006392A2 (pt) 2021-07-06
US11623924B2 (en) 2023-04-11
AU2019362753A1 (en) 2021-05-20
TW202024091A (zh) 2020-07-01
WO2020081257A1 (fr) 2020-04-23
CA3114672A1 (fr) 2020-04-23
US20210179587A1 (en) 2021-06-17
IL281884A (en) 2021-05-31
JOP20210060A1 (ar) 2023-01-30
UY38403A (es) 2020-04-30
EP3860712A1 (fr) 2021-08-11
US20230265080A1 (en) 2023-08-24
CO2021005884A2 (es) 2021-05-20
CN113164761A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
MA53827A (fr) Modulateurs de l'alpha -1 antitrypsine
CL2021001078A1 (es) 2-amino-n-heteroarilo-nicotinamidas como inhibidores de nav1.8.
DK3687994T3 (da) Gadolinium-bærende pcta-baserede kontrastmidler
MA46652A (fr) Polythérapie pour l'inhibition de c3
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
MA54386A (fr) Modulateurs de trex1
MA53924A (fr) Modulateurs de l'expression d'apol1
IT201800003333A1 (it) Veicolo modulare
MA46615A (fr) Inhibiteurs de nav1.7 de type acyl-sulfonamide
DK3801427T3 (da) Selvbalancerende køretøj
DE112019002757A5 (de) Steuerbare Einführungshülse
ES1216564Y (es) Dispensador de fundas de protección manual
DK3840596T3 (da) Sammensætning
MA51645A (fr) Modulateurs de l'expression de dnm2
DK3840144T3 (da) Skifteanordningen
ES1225190Y (es) Conjunto de ducha
ITUA20163609A1 (it) "micro-cogeneratore".
ES1230426Y (es) Aparcavehiculos modular escamoteable
ES1232554Y (es) Bolardo de senalizacion viaria
ES1242619Y (es) Arenero
UA37466S (uk) Крапельниця
UA37465S (uk) Крапельниця
UA42087S (uk) Несесер дорожній
UA42085S (uk) Несесер дорожній
UA42083S (uk) Несесер дорожній